I understand the appeal of a device that promises to make your brain feel better. Something you can put on, turn on, and use while the rest of your life continues around you sounds wonderfully convenient. I've used NeoRhythm myself, so my curiosity about this subject comes with a personal connection. I also want to know what the different devices are actually doing, because the phrase light therapy can cover an awfully confusing collection of things.
There's a bright lamp you sit beside, a device that delivers near-infrared light toward the head, and a wearable that uses pulsed magnetic fields. Those are three different approaches. Bright-light therapy has an established role in winter-pattern seasonal depression; the research on near-infrared devices for depression is still developing, with mixed trial results. Once I separated those ideas, the whole subject became considerably easier to follow, although considerably harder to fit into a cheerful advertisement.
The Bright Lamp Has a Real Place in Depression Treatment
The National Institute of Mental Health describes bright-light therapy as a mainstay for winter-pattern seasonal affective disorder, or SAD. Its example involves a UV-filtered, 10,000-lux light box used for about 30 to 45 minutes, usually in the morning. Those are features of a treatment protocol, with timing and suitability discussed with a health care provider. The lamp gives a controlled bright-light exposure during the darker part of the year.
I love autumn, which makes me particularly interested in the fact that a season can mean very different things to different people. I can be admiring the leaves while somebody else is dealing with a recurring depressive episode. A favorite month and a serious health condition can occupy the same calendar. The light-box approach has a history of clinical use that deserves its own explanation, rather than getting lost among photographs of glowing headsets.
Your Eyes Give the Brain Information About the Time
Light helps synchronize the body’s internal clocks, including the timing of sleep and wakefulness. Information received through the eyes helps the brain respond to the daily light-dark cycle. Bright artificial light late in the evening can interfere with the normal rise in melatonin. That helps explain why the timing of a light treatment matters, even when the thing on the desk looks like a fairly ordinary lamp.
My brain likes to think it runs the place, so I enjoy learning how much information it's taking from the environment. There's something almost funny about a body having its own timing system while we keep inventing ways to illuminate every hour of the day. Then the practical question becomes when a particular person needs a particular kind of light. A description of light as universally relaxing leaves quite a lot of that story out.
Bright Light Has Been Studied Beyond Seasonal Depression
In a randomized trial published in 2016, 122 adults with nonseasonal major depression were assigned to bright light, fluoxetine, a combination, or a placebo condition. Over eight weeks, light alone and the combination performed better than placebo on the main depression rating measure. The combination produced the most consistent results. That is useful evidence for this particular approach and patient group.
I find the combination especially interesting because it's very easy to talk about treatments as though they're competing contestants. One gets a dramatic entrance, another gets voted off, and everybody wants a single winner. Here, the researchers actually tested the possibility of using approaches together. The result belongs to that trial, with its particular lamp and schedule, which becomes important as soon as the conversation turns to a completely different kind of device.
Near-Infrared Treatment Takes a Different Route
Transcranial photobiomodulation, usually shortened to tPBM, involves delivering light toward the brain through the scalp and skull. In a 2012 experiment using preserved cadaver tissue, researchers measured transmission of red and near-infrared light. Near-infrared light passed through the tissues more readily under the conditions they tested. That gives researchers a physical question they can investigate, with the important qualification that preserved tissue differs from a living person.
I can see why the idea attracts attention. You start with something as familiar as light and end up asking how much reaches a particular tissue. The amount arriving matters, along with the wavelength, placement and equipment. Seeing a red glow on somebody's forehead tells me very little about those details, however impressive the photograph might be. The skull has rather inconveniently inserted itself between the product picture and the intended destination.
The Early Depression Trial Was Small and Interesting
Researchers have been interested in whether near-infrared exposure can influence cellular energy processes involving mitochondria. The 2018 ELATED-2 pilot trial tested repeated near-infrared treatments in people with major depression and reported encouraging antidepressant signals. Twenty-one participants were randomized, and 13 completed the study. The authors called for replication because of the small sample. It was a reason to keep investigating.
That is the sort of result that makes me curious about what comes next. A small trial can start a much larger conversation, especially when the treatment would be convenient if it worked reliably. I can understand the excitement around a possibility like that. I also want to stay with the story long enough to see what happens when another group of people receives another carefully controlled test.
Later Trials Produced a More Complicated Picture
In the ELATED-3 trial, published in 2022, the analysis included 49 people with major depression. This low-level near-infrared protocol produced no significant advantage over sham treatment on the depression scales used. The researchers discussed whether the dose and treatment schedule were insufficient. That leaves a specific unsuccessful protocol and a question about how other protocols might behave.
I find that result useful precisely because it makes the next question clearer. There are settings to investigate and outcomes to compare, rather than one grand answer about everything involving light. The term near-infrared can make two devices sound closely related while leaving out a great deal about what each one delivers. It's a little like being told two wines contain grapes and being expected to infer everything else about them from there.
A Wearable Study Found a Sleep Benefit, With a Different Mood Result
A 2025 randomized trial involving 48 outpatients tested a self-administered wearable tPBM device alongside ongoing care. Participants used active or sham treatment over eight weeks. Depression scores improved in both groups, with no significant difference between them. The active group did show a greater improvement in reported sleep quality. The study was small, and follow-up was limited.
Sleep and mood can matter enormously to the same person, so I understand why both outcomes were measured. They still answer different questions. I would want a description of that study to include both results, because a better night and an antidepressant effect are different claims. The interesting part is that researchers can follow those outcomes separately and work out which question a device may actually help answer.
A Change on a Brain Scan Has Its Own Meaning
In a 2026 study of 31 people with major depression, investigators delivered different near-infrared doses during MRI scanning. One dose increased a measure of blood-oxygenation-related signal variation, another decreased it, and a pulsed dose produced no significant change in that measure. Single administrations did not significantly improve depression severity compared with sham. The findings help with questions about biological effects and future dosing.
This is where I have to resist being overly impressed by a brain image. I find them fascinating, and I would happily get distracted by the explanation of how the picture was made. But a measurable change has to be connected to the outcome we're interested in. For this article, that outcome is whether somebody's depression improves. The imaging result gives researchers another piece to investigate on the way there.
NeoRhythm Uses Magnetic Fields
The NeoRhythm wearable belongs in a separate part of this discussion. Its manufacturer describes it as a PEMF wellness device, using pulsed electromagnetic fields and programs marketed for relaxation, sleep and focus. It supplies magnetic pulses, rather than the optical exposure used in the near-infrared trials above. Borrowing the results of those trials to explain this headband would skip over that fairly substantial difference.
I've written about my own use of NeoRhythm, and I can keep that experience in the conversation while being clear about what it can establish. My impression of an experience is personal; showing that a device treats diagnosed depression calls for a different kind of evidence. The manufacturer's medical disclaimer says its statements are intended for wellness rather than diagnosing, treating or curing disease. It also lists contraindications, including pregnancy, epilepsy and certain implants, which deserve attention before use.
Clinical Magnetic Stimulation Is Another Specific Treatment
Repetitive transcranial magnetic stimulation, or rTMS, is a clinical treatment with evidence and FDA clearance for depression in specified circumstances. A clinician uses a coil positioned near a particular brain area, with a defined treatment plan. The magnetic field creates electrical currents that stimulate neural circuits. That description concerns medical rTMS systems and the evidence for those systems.
I can see how easily the words magnetic stimulation could make a home wearable and a clinic-based treatment sound interchangeable. Both descriptions involve magnetism, which is enough to make me start mentally connecting them. Their actual delivery and clinical evidence still need to be considered separately. I like knowing a treatment like rTMS exists, while keeping its results attached to the equipment and procedures that produced them.
The Safety Part Belongs Beside the Promise
Bright-light treatment can cause headaches, eye strain, agitation or changes in sleep. The International Society for Bipolar Disorders’ clinical recommendations emphasize clinician guidance and monitoring, particularly because hypomania or mania can emerge in susceptible people. Eye conditions and medications that increase light sensitivity also matter. These are reasons to discuss treatment with a qualified provider, including the kind of depression being treated, rather than choosing a schedule from a product photograph.
The small near-infrared trials described above generally reported tolerable treatments, which is encouraging for further research. Their size and duration leave questions about wider use, and an unrelated retail device has its own characteristics. I'd want to know what has actually been tested before putting a strong medical claim beside it. An appealing object can arrive with instructions and still leave the most important question for a conversation with a clinician.
The Shopping Links Refer to Very Different Things
For readers looking back at the products mentioned here, the cosmetic LED face-mask listing and the bright-light lamp listing refer to different kinds of equipment. A skin-care product cannot inherit an antidepressant claim from a trial of a separate device. For a bright-light box, a clinician can help assess the appropriate specifications, positioning and timing. The listing itself establishes none of those clinical outcomes.
The decorative crystal-headband listing and the seller's red-light lamp listing are here for anyone following those earlier mentions. A decorative accessory can be beautiful to wear, and I certainly appreciate a beautiful object. Claims about treating depression need their own evidence, tied to a specific device and use. I would rather know which kind of purchase I'm considering before expecting it to do something quite different.
Hope Deserves an Honest Answer
Depression can affect sleep, concentration, appetite and day-to-day functioning, and established treatment options include psychotherapy, medication and, for certain situations, clinical brain stimulation. A qualified health care provider can help choose a plan and review whether a light treatment fits. Existing treatment should be changed with that provider's guidance. This article is general information, and a new device is a reason to have that conversation rather than interrupt care.
The appeal of a convenient new option still makes sense to me. I'd love for the useful choices to keep expanding, particularly for people who have had a difficult time finding relief. I can be hopeful about that without being certain where the next result will lead. Honestly, my curiousity about what researchers might find is a large part of why I wanted to stay with this subject after the simple version stopped being simple.
So does light therapy help depression? Bright-light treatment has a real clinical role, especially in winter-pattern SAD, and research also supports its use in certain nonseasonal settings. Near-infrared treatment remains an area of investigation with mixed results, while NeoRhythm is a different technology with different claims. I still find the possibility interesting. I also think the person considering a purchase deserves the details before the beautiful photograph has done all the persuading.
Related Reads
Sources
NIMH. Seasonal affective disorder and bright-light treatment.
Lam and colleagues. Bright light, fluoxetine and nonseasonal depression. JAMA Psychiatry, 2016.
Jagdeo and colleagues. Red and near-infrared transmission in a cadaveric model. PLOS ONE, 2012.
Cassano and colleagues. The ELATED-2 pilot trial. Photomedicine and Laser Surgery, 2018.
Iosifescu and colleagues. The ELATED-3 randomized trial. Journal of Clinical Psychiatry, 2022.
Iosifescu and colleagues. Dose-dependent imaging effects in depression. Brain Stimulation, 2026.
Omnipemf. NeoRhythm product description; manufacturer’s claims.
Geoffroy and the ISBD task force. Clinical recommendations for bipolar light therapy, 2025.
